Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Galmed Pharmaceuticals (GLMD)
NASDAQ:GLMD
Holding GLMD?
Track your performance easily
GLMD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.68 - $23.80
Previous Close$2.87
Volume34.86K
Average Volume (3M)2.63M
Market Cap
$4.59M
Enterprise Value-$317.43K
Total Cash (Recent Filing)$5.11M
Total Debt (Recent Filing)$41.00K
Price to Earnings (P/E)―
Beta1.47
Next Earnings
May 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.04
Shares Outstanding643,690
10 Day Avg. Volume57,297
30 Day Avg. Volume2,631,231
Standard Deviation0.28
R-Squared0.02
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.14
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.35
Enterprise Value/Ebitda0.03
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Galmed Pharmaceuticals News
PremiumCompany Announcements
Galmed Pharmaceuticals Embraces Market with New Sales Agreement
PremiumCompany Announcements
Galmed Pharmaceuticals Strengthens Financial Position Amid Losses
PremiumCompany Announcements
Galmed Pharmaceuticals Amends Equity Purchase Agreement
PremiumCompany Announcements
Galmed Reports Breakthrough in MASH Treatment
PremiumCompany Announcements
Galmed Pharmaceuticals Calls for Capital Increase VoteOwnership Overview
6.20%
Insiders
0.11% Mutual Funds
<0.01% Other Institutional Investors
93.69% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
GLMD FAQ
What was Galmed Pharmaceuticals’s price range in the past 12 months?
Galmed Pharmaceuticals lowest stock price was $2.68 and its highest was $23.80 in the past 12 months.
What is Galmed Pharmaceuticals’s market cap?
Currently, no data Available
When is Galmed Pharmaceuticals’s upcoming earnings report date?
Galmed Pharmaceuticals’s upcoming earnings report date is May 07, 2025 which is in 162 days.
How were Galmed Pharmaceuticals’s earnings last quarter?
Galmed Pharmaceuticals released its earnings results on May 08, 2024. The company reported -$0.234 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.234.
Is Galmed Pharmaceuticals overvalued?
According to Wall Street analysts Galmed Pharmaceuticals’s price is currently Overvalued.
Does Galmed Pharmaceuticals pay dividends?
Galmed Pharmaceuticals does not currently pay dividends.
What is Galmed Pharmaceuticals’s EPS estimate?
Galmed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Galmed Pharmaceuticals have?
Galmed Pharmaceuticals has 1,656,992 shares outstanding.
What happened to Galmed Pharmaceuticals’s price movement after its last earnings report?
Galmed Pharmaceuticals reported an EPS of -$0.234 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.499%.
Which hedge fund is a major shareholder of Galmed Pharmaceuticals?
Among the largest hedge funds holding Galmed Pharmaceuticals’s share is PYA Waltman Capital, LLC. It holds Galmed Pharmaceuticals’s shares valued at N/A.
---
Galmed Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
GLMD Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 6.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.3%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.51%
12-Months-Change
Fundamentals
Return on Equity
-37.32%
Trailing 12-Months
Asset Growth
18.78%
Trailing 12-Months
Company Description
Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on the development of the liver targeted stearoyl-coenzyme A desaturase-1 modulator Aramchol, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. The Aramchol is a synthetic conjugate of cholic acid, or a type of bile acid, and arachidic acid, or a type of saturated fatty acid, both of which, in their non-synthetic forms, are naturally occurring. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
---
GLMD Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---